Navigating the Frontier of Hematologic Malignancy Therapies

This activity will cover the latest advances in the therapeutic management of hematologic malignancies, including bispecific antibodies, CAR-T products, proteolysis-targeting chimeras, and antibody-drug conjugates — with an emphasis on novel targets and approaches. The prognostic role of circulating tumor DNA is also explored.

View Courses

Jointly provided by The Leukemia & Lymphoma Society and RMEI Medical Education, LLC.

The educational portion of this program is supported by an independent educational grant from AstraZeneca Pharmaceuticals LP. Additional funding provided by The Leukemia & Lymphoma Society

Series Courses

02 22 812 vl ash recommended courses 496x244 px 002

Bispecific Antibodies Latch Onto Advances – Module 1

CME: 0.5
VIEW COURSE
02 22 812 vl ash recommended courses 496x244 px 002 1

Approaches Beyond Classic CAR T-Cells – Module 2

CME: 0.5
VIEW COURSE
02 22 812 vl ash recommended courses 496x244 px 002 1 1

PROTACs: A Paradigm Shift in Drug Discovery – Module 3

CME: 0.5
VIEW COURSE
02 22 812 vl ash recommended courses 496x244 px 002 2

Novel ADC Target Hunting in Pediatric AML – Module 4

CME: 0.5
VIEW COURSE
02 22 812 vl ash recommended courses 496x244 px 002 3

Cell-Free DNA Potential in Guiding Therapies and Q&A – Module 5

CME: 1
VIEW COURSE